These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23467116)

  • 1. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
    Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
    Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Dickkopf 1 levels in sclerostin deficiency.
    van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
    de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
    Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
    Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
    Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: A prospective, cross-sectional study.
    Yang HY; Wu DA; Chen MC; Hsu BG
    Diab Vasc Dis Res; 2019 May; 16(3):281-288. PubMed ID: 30547685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
    Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
    Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.
    He XW; Wang E; Bao YY; Wang F; Zhu M; Hu XF; Jin XP
    Atherosclerosis; 2016 Oct; 253():22-28. PubMed ID: 27573735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis.
    Napimoga MH; Nametala C; da Silva FL; Miranda TS; Bossonaro JP; Demasi AP; Duarte PM
    J Clin Periodontol; 2014 Jun; 41(6):550-7. PubMed ID: 24576302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sclerostin and DKK1 in relation to exercise against bone loss in experimental bed rest.
    Belavý DL; Baecker N; Armbrecht G; Beller G; Buehlmeier J; Frings-Meuthen P; Rittweger J; Roth HJ; Heer M; Felsenberg D
    J Bone Miner Metab; 2016 May; 34(3):354-65. PubMed ID: 26056021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum sclerostin levels and metabolic bone diseases].
    Yamauchi M; Sugimoto T
    Clin Calcium; 2013 Jun; 23(6):877-83. PubMed ID: 23719501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.